{"id":302,"date":"2026-08-29T05:02:46","date_gmt":"2026-08-29T05:02:46","guid":{"rendered":"https:\/\/dentaltransitions.com\/articles\/vet-dso-partners-dental-practice\/"},"modified":"2026-08-29T05:02:46","modified_gmt":"2026-08-29T05:02:46","slug":"vet-dso-partners-dental-practice","status":"publish","type":"post","link":"https:\/\/dentaltransitions.com\/articles\/vet-dso-partners-dental-practice\/","title":{"rendered":"How to Vet DSO Partners Before Selling Your Dental Practice"},"content":{"rendered":"<h2>Key Takeaways for Dentists Considering a DSO Sale<\/h2>\n<ul>\n<li>\n<p>DSO negotiations are inherently one-sided, so sellers benefit from a clear, repeatable due-diligence process to balance the discussion.<\/p>\n<\/li>\n<li>\n<p>Four practical steps \u2013 ownership investigation, reference interviews, employment-agreement review, and staff\/vendor checks \u2013 create a solid vetting framework.<\/p>\n<\/li>\n<li>\n<p>A 10-question script, red-flag checklist, and seller scorecard give you objective ways to compare multiple DSO offers.<\/p>\n<\/li>\n<li>\n<p>Competitive, multi-buyer processes often produce stronger terms and reveal which platforms are truly well-capitalized and seller-friendly.<\/p>\n<\/li>\n<li>\n<p>McLerran &amp; Associates uses this methodology on every engagement; <a target=\"_blank\" rel=\"noopener noreferrer nofollow\" href=\"https:\/\/dentaltransitions.com\/contact-us\/\">schedule a free, confidential discovery call<\/a> to apply these tools to your transition.<\/p>\n<\/li>\n<\/ul>\n<h2>Key Deal Terms Explained for Dental Owners<\/h2>\n<p>This guide uses several financial and legal terms that can affect your outcome. The list below explains each one in plain language.<\/p>\n<ul>\n<li>\n<p><strong>EBITDA<\/strong> \u2013 Earnings Before Interest, Taxes, Depreciation, and Amortization. This is the profit figure DSOs use to value practices. It removes financing and accounting choices so it reflects ongoing operating cash flow.<\/p>\n<\/li>\n<li>\n<p><strong>LOI<\/strong> \u2013 Letter of Intent. This non-binding document sets the headline price and key deal terms before formal contracts are drafted. Most deal re-trading happens between LOI and closing.<\/p>\n<\/li>\n<li>\n<p><strong>Diligence<\/strong> \u2013 The buyer\u2019s formal investigation of your financials, operations, and legal standing after you sign an LOI.<\/p>\n<\/li>\n<li>\n<p><strong>Earnout<\/strong> \u2013 A contingent payment tied to post-close performance targets, such as maintaining a defined EBITDA level. Only the cash-at-close portion of a deal is guaranteed. Earnouts depend on hitting benchmarks after the buyer controls operations.<\/p>\n<\/li>\n<li>\n<p><strong>JV (joint-venture) equity<\/strong> \u2013 Retained ownership at the individual practice level. JV equity usually generates ongoing distributions but often has a lower ceiling on upside.<\/p>\n<\/li>\n<li>\n<p><strong>Holding-company (HoldCo) equity<\/strong> \u2013 Ownership rolled into the DSO\u2019s parent entity. HoldCo equity typically does not generate regular distributions. Its value depends on the entire platform\u2019s performance at a future sale or recapitalization.<\/p>\n<\/li>\n<li>\n<p><strong>Recapitalization (recap)<\/strong> \u2013 A transaction where the DSO\u2019s private equity backer sells the platform to a new investor. This creates a liquidity event for rollover equity holders. Recaps typically occur every 3 to 7 years and are the main way to monetize HoldCo equity.<\/p>\n<\/li>\n<\/ul>\n<h2>Step 1: Evaluating Ownership Structure and PE Backer<\/h2>\n<p>Effective vetting starts with a clear picture of who owns the DSO. Most large DSOs are backed by private equity firms that supply the capital for acquisitions and growth. The PE backer\u2019s track record, fund vintage, and remaining hold period can be some of the main factors that influence whether your rollover equity has meaningful value at the next recap.<\/p>\n<p>To conduct this investigation, gather the DSO\u2019s management services agreement (MSA) summary, its most recent audited financials or quality-of-earnings report if available, and information on the PE sponsor\u2019s prior dental-sector exits. These documents reveal two critical decision points: fund age (a fund in year 7 of a 10-year life has less runway than one in year 2) and whether the platform is growing same-store revenue or only growing through acquisitions. Together, these factors highlight the platform\u2019s underlying health, and sustainable profitability, infrastructure, and long-term scalability can be some of the main indicators that separate durable platforms from those that grew quickly on leverage and now face pressure.<\/p>\n<p>Once you have this ownership picture, you face a strategic choice about process design. The trade-off at this step is speed versus optionality. Engaging a single DSO quickly can feel efficient, yet a competitive process among multiple vetted buyers, typically generating around 10 offers over 45 to 60 days in a well-run advisory engagement, often produces stronger terms and shows which buyers are genuinely well-capitalized.<\/p>\n<h2>Step 2: Interviewing Past Sellers to the DSO<\/h2>\n<p>Past-seller interviews reveal how the DSO behaves after closing. A DSO\u2019s pitch deck describes the partnership it intends to offer, while conversations with dentists who sold to that platform 18 to 36 months ago describe the partnership it actually delivered. Request a list of 5 to 10 past sellers directly from the DSO, then ask your own network or your advisor for introductions to additional sellers who are not on that list.<\/p>\n<p>Keep reference conversations focused on three areas. First, confirm whether post-close operations matched pre-LOI representations. Second, ask whether staff was retained and treated well. Third, explore whether the earnout was achievable given the operational changes the DSO made after closing. When expectations are not aligned, those issues tend to surface when it matters most, and past sellers can be some of the clearest signals of where misalignment exists.<\/p>\n<p>Consistent concerns from past sellers can justify stepping back and reassessing your options. If you want help running a structured reference process and tapping into McLerran &amp; Associates\u2019 vetted buyer network, including DSOs that have been blacklisted for poor post-close environments, <a target=\"_blank\" rel=\"noopener noreferrer nofollow\" href=\"https:\/\/dentaltransitions.com\/contact-us\/\">find out which buyers have a track record of happy sellers in your market by scheduling a confidential discovery call<\/a>.<\/p>\n<h2>The 10 Questions to Ask Every DSO<\/h2>\n<p>This 10-question script works best when you ask each question to both the DSO\u2019s development officer and its past sellers. Differences between the two sets of answers can be highly informative.<\/p>\n<ol>\n<li>\n<p>Who owns the DSO at the holding-company level, what is the PE fund\u2019s vintage year, and how many years remain in the fund\u2019s life?<\/p>\n<\/li>\n<li>\n<p>Is the platform profitable on a same-store basis, meaning at the offices it already owns, not just in aggregate?<\/p>\n<\/li>\n<li>\n<p>What percentage of total consideration is cash at close, what percentage is rollover equity, and what percentage is earnout?<\/p>\n<\/li>\n<li>\n<p>Is rollover equity held at the JV (practice) level or the HoldCo (platform) level, and what liquidation preferences, dilution provisions, and tag-along rights apply?<\/p>\n<\/li>\n<li>\n<p>What is the precise EBITDA definition used in the earnout, including which post-close management fees and central cost allocations are deducted before the metric is measured?<\/p>\n<\/li>\n<li>\n<p>What clinical autonomy protections, such as treatment planning, lab selection, and scheduling flow, are written into the employment agreement and MSA, not just described verbally?<\/p>\n<\/li>\n<li>\n<p>What is the compensation structure post-close, and is it based on production or net collections?<\/p>\n<\/li>\n<li>\n<p>What is the non-compete geography and duration, and has the DSO enforced non-competes against departing dentists in the past?<\/p>\n<\/li>\n<li>\n<p>Can you provide references from 5 sellers who affiliated 18 to 36 months ago, including at least 2 not on your standard reference list?<\/p>\n<\/li>\n<li>\n<p>What is the anticipated timeline and structure of the next recapitalization, and what multiple is the platform currently targeting for that exit?<\/p>\n<\/li>\n<\/ol>\n<h2>Step 3: Reviewing Employment Terms and Clinical Autonomy<\/h2>\n<p>Your employment agreement shapes your daily professional life after closing. Every protection a seller wants for clinical autonomy, scheduling authority, staff retention, and information rights must appear in writing in either the operating agreement, the MSA, or the employment contract, not only in a verbal LOI assurance.<\/p>\n<p>To conduct this review, gather the full draft employment agreement, the MSA summary, and the PC operating agreement. Within these documents, focus on provisions that directly affect your post-close autonomy and economics. These include the compensation formula, where production-based formulas are generally more seller-favorable than collections-based ones, the non-compete geography and duration, termination provisions and notice periods, and whether the agreement ties staff bonuses to revenue or sales metrics. Clinical discretion over treatment decisions should be reserved solely for the licensed practice owner, and that protection should appear explicitly in the contract language.<\/p>\n<p>Non-compete enforceability varies significantly by state. Several states limit or prohibit dental non-competes, including California, Colorado, Minnesota, Oklahoma, and North Dakota, which can be a material factor if you practice in or near those jurisdictions. A dental-transaction-specialized attorney can review these provisions before you sign any LOI.<\/p>\n<h2>Step 4: Assessing Staff Impact and Vendor Reputation<\/h2>\n<p>Staff continuity and vendor relationships often feel the impact of a DSO integration first. <a target=\"_blank\" rel=\"noindex nofollow\" href=\"https:\/\/beckersdental.com\/dentists\/dentistry-is-35-consolidated-7-notes-on-the-state-of-dental-ma\">Provider risk, clinical continuity, and declining financial performance<\/a> are leading reasons DSOs walk away from deals, and those same issues can be valid reasons for a seller to walk away from a DSO.<\/p>\n<p>For this step, collect the DSO\u2019s stated HR and benefits policies, its standard vendor and lab approval list, and references from staff at practices the DSO acquired 12 to 24 months ago. Key decision points include whether the DSO requires staff to re-apply for their positions post-close, whether it mandates a specific practice management software migration, and whether it imposes approved supplier lists that would change your clinical materials. Integration readiness, scheduling, collections workflow, and management depth can be some of the main indicators of whether a DSO can absorb your practice without disrupting the patient experience your staff has built.<\/p>\n<p>The main trade-off here is fit versus price. A higher-bidding DSO with a weak integration track record can cost more in staff turnover, patient attrition, and earnout shortfalls than the premium it offered at signing. McLerran &amp; Associates focuses on both price and fit and has blacklisted DSOs known for creating poor post-close environments so they never reach the table. <a target=\"_blank\" rel=\"noopener noreferrer nofollow\" href=\"https:\/\/dentaltransitions.com\/contact-us\/\">Learn which buyers protect staff and patients in your specialty by starting with a confidential discovery call<\/a>.<\/p>\n<h2>Red-Flag Reference for DSO Vetting<\/h2>\n<p>The warning signs below, and their likely consequences, can appear at any point in the vetting process.<\/p>\n<ul>\n<li>\n<p><strong>DSO declines to provide past-seller references outside its curated list.<\/strong> Consequence: No independent verification of post-close representations and higher risk of misalignment on autonomy and earnout.<\/p>\n<\/li>\n<li>\n<p><strong>Earnout EBITDA definition includes post-close management fees and central cost allocations at the buyer\u2019s discretion.<\/strong> Consequence: The buyer controls the inputs that determine whether you get paid, which can make the earnout effectively unachievable.<\/p>\n<\/li>\n<li>\n<p><strong>Rollover equity terms omit liquidation preferences, dilution provisions, or information rights.<\/strong> Consequence: Opaque equity terms can result in the retained equity being worth substantially less than initially represented.<\/p>\n<\/li>\n<li>\n<p><strong>PE fund is in year 7 or later of a 10-year life with no announced recap.<\/strong> Consequence: Compressed timeline for your equity to reach a liquidity event and higher risk of a distressed or below-target exit.<\/p>\n<\/li>\n<li>\n<p><strong>Employment agreement uses vague for-cause termination language such as \u201cfailure to meet practice standards.\u201d<\/strong> Consequence: Employer flexibility to terminate without notice and potentially enforce non-competes without severance.<\/p>\n<\/li>\n<li>\n<p><strong>DSO\u2019s same-store revenue is flat or declining while headline growth comes only from new acquisitions.<\/strong> Consequence: Platform economics may be weaker than they appear, so rollover equity value depends on a growth story that may not materialize.<\/p>\n<\/li>\n<li>\n<p><strong>Clinical autonomy protections exist only in the LOI, not in the executed employment agreement or MSA.<\/strong> Consequence: Verbal assurances are unenforceable, leaving post-close clinical constraints without contractual remedies.<\/p>\n<\/li>\n<\/ul>\n<h2>Seller Scorecard Template for Comparing DSOs<\/h2>\n<p>A simple scorecard can make comparisons between DSO finalists more objective. Score each DSO on the categories below using a 1\u20135 scale, where 1 means unacceptable and 5 means excellent. Weight financial and contractual categories more heavily if cash-at-close and earnout certainty matter most, and weight cultural and autonomy categories more heavily if legacy and staff continuity are your priorities.<\/p>\n<ul>\n<li>\n<p>PE backer track record and fund runway (financial)<\/p>\n<\/li>\n<li>\n<p>Same-store profitability and platform growth quality (financial)<\/p>\n<\/li>\n<li>\n<p>Cash-at-close percentage and earnout structure clarity (financial)<\/p>\n<\/li>\n<li>\n<p>Rollover equity terms, including liquidation preferences, dilution, and information rights (financial)<\/p>\n<\/li>\n<li>\n<p>Clinical autonomy protections in writing (contractual)<\/p>\n<\/li>\n<li>\n<p>Non-compete geography, duration, and enforceability in your state (contractual)<\/p>\n<\/li>\n<li>\n<p>Compensation formula favorability (contractual)<\/p>\n<\/li>\n<li>\n<p>Past-seller reference quality and consistency with DSO representations (cultural)<\/p>\n<\/li>\n<li>\n<p>Staff retention and HR policy post-close (cultural)<\/p>\n<\/li>\n<li>\n<p>Vendor and lab flexibility (operational)<\/p>\n<\/li>\n<\/ul>\n<h2>Challenges and Troubleshooting in DSO Sales<\/h2>\n<p><strong>Valuation gaps.<\/strong> A DSO offer that falls well below your expectations often reflects an unsupported EBITDA, especially add-backs that have not been documented or defended. A diligence-grade EBITDA analysis completed before going to market helps control this narrative and can reduce re-trading. DSO deals most often lose value after LOI when diligence reveals unsupported add-backs or weaker collections than expected.<\/p>\n<p><strong>Incomplete financials.<\/strong> Buyers who receive disorganized financials assign a risk premium that compresses the multiple because they assume hidden problems. To avoid this penalty, produce clean, benchmarked financials before the process begins, not only in response to a buyer\u2019s diligence request, and demonstrate transparency that reduces the uncertainty driving down offers.<\/p>\n<p><strong>Buyer-fit concerns.<\/strong> Consistent concerns from reference interviews about a DSO\u2019s post-close behavior can be treated as disqualifying rather than negotiable. A more protective response is to return to a competitive process and advance a different finalist instead of relying on assurances that conflict with past-seller experiences.<\/p>\n<p><strong>Confidentiality risks.<\/strong> Staff and patient relationships represent the goodwill that makes your practice valuable. A well-run advisory process keeps the sale confidential until closing, using a virtual data room and NDAs before sharing financial information. Going to market without these controls can create staff anxiety and patient attrition before the deal closes.<\/p>\n<h2>Measuring Success in Your Vetting Process<\/h2>\n<p>Several objective indicators can show that your vetting process is working as intended. These include multiple competing offers from pre-qualified buyers rather than a single inbound LOI, an EBITDA analysis that survives buyer diligence without material re-trading, and employment agreement terms that match pre-LOI representations on autonomy and compensation. Additional signs include past-seller references that align with the DSO\u2019s pitch and a cash-at-close percentage that reflects your liquidity priorities. North American DSO deal activity has shifted, with structures featuring more contingencies and less upfront cash than deals completed a few years ago, which makes the quality of the competitive process and the defensibility of EBITDA especially consequential.<\/p>\n<h2>Advanced Deal Structures for Larger Practices<\/h2>\n<p>Owners with practices generating substantial EBITDA may see offers that include phased exit structures. These can include platform acquisitions where the practice becomes the foundation of a new DSO and the owner steps into a leadership role. These structures introduce additional complexity around governance, equity class, and management incentive alignment, and they usually warrant separate financial modeling.<\/p>\n<p>Owners who are not yet ready to sell can still benefit from periodic reassessment. A valuation completed today establishes a baseline, and revisiting it annually keeps the decision grounded in current data rather than assumptions formed during a different market environment.<\/p>\n<h2>Conclusion: Applying a Structured Vetting Framework<\/h2>\n<p>Vetting a DSO partner works best as a structured four-step process that covers ownership and PE-backer investigation, reference interviews with past sellers, employment-agreement and clinical-autonomy review, and staff-impact and vendor-reputation checks. The 10-question script above offers a starting point, and the red-flag reference and seller scorecard help make the evaluation repeatable and comparable across multiple finalists.<\/p>\n<p>McLerran &amp; Associates applies this methodology on every DSO engagement, running a structured, auction-like bid process among a vetted pool of well-qualified buyers, with poorly run DSOs blacklisted before they reach the table. With roughly 2,000 successful practice sales, approximately $2 billion in closed transaction volume, and more than 10,000 practices evaluated, the firm brings the depth of a dental-only sell-side advisor to one of the most consequential financial decisions of a dentist\u2019s career.<\/p>\n<p><a target=\"_blank\" rel=\"noopener noreferrer nofollow\" href=\"https:\/\/dentaltransitions.com\/contact-us\/\">Explore what a competitive, well-structured process could mean for your outcome by scheduling a confidential discovery call with McLerran &amp; Associates<\/a>.<\/p>\n<h2>Frequently Asked Questions<\/h2>\n<h3>How do I know if a DSO\u2019s rollover equity is actually worth taking?<\/h3>\n<p>Rollover equity, the portion of your deal paid as ownership in the DSO rather than cash, can deliver meaningful upside if the platform sells at a higher valuation in a future recapitalization, but it carries real investment risk. Before assigning value to it, request written answers on at least four points: the equity class, such as preferred versus common and any liquidation preferences, the current leverage ratio of the platform, the anticipated timeline and structure of the next recap, and any dilution provisions that could reduce your percentage before that event. A DSO that cannot or will not answer these questions clearly may be signaling that the equity terms do not favor the seller. McLerran &amp; Associates helps clients model the risk-adjusted value of rollover equity across multiple scenarios, including conservative assumptions about recap timing and exit multiples, so comparisons between cash-heavy and equity-heavy offers rely on real numbers rather than headline figures.<\/p>\n<h3>What should I look for in a DSO\u2019s employment agreement before signing an LOI?<\/h3>\n<p>The employment agreement shapes your day-to-day professional life for the 3 to 5 years following the sale, and its terms can be more consequential than the headline purchase price. The provisions that most frequently create problems include the compensation formula, where production-based structures are generally more seller-favorable than collections-based ones, the non-compete geography and duration and whether your state enforces non-competes at all, the for-cause termination language, where vague standards give the buyer flexibility to terminate and enforce the non-compete without severance, and the clinical autonomy protections. Every autonomy protection, including treatment planning, lab selection, and scheduling flow, should appear in the executed employment agreement or MSA, not only in the LOI. Verbal assurances made during the courtship phase are unenforceable once the deal closes. A dental-transaction-specialized attorney can review the full agreement before you sign anything.<\/p>\n<h3>How many DSO offers should I expect before choosing a buyer?<\/h3>\n<p>In a well-run, competitive advisory process, a premier practice can expect multiple qualified offers within 45 to 60 days. As mentioned earlier, this competitive dynamic is what often drives better terms. When a DSO knows it is competing against several other qualified buyers, it tends to bid more aggressively on price, offer more favorable terms on earnout structure and clinical autonomy, and show less inclination to re-trade the deal during diligence. Owners who engage a single inbound DSO directly do not benefit from that leverage. The competitive process also reveals the market\u2019s view of your practice, which can make the final choice between price and fit more informed.<\/p>\n<h3>What are the most common reasons a DSO deal falls apart after the LOI is signed?<\/h3>\n<p>Many post-LOI deal failures trace back to a small set of causes. Unsupported add-backs in the EBITDA analysis can be stripped out by the buyer\u2019s quality-of-earnings team during diligence, which reduces the agreed valuation. Earnout definitions that give the buyer discretion over cost allocations can affect whether the target is met. Employment agreement terms that differ from what was represented in the LOI can create late-stage friction. Confidentiality failures that trigger staff anxiety or patient attrition before closing can weaken the goodwill the buyer is paying for. A diligence-grade EBITDA analysis completed before going to market, with every add-back documented, can reduce the first risk, and an experienced sell-side advisor who has seen these failure modes before can structure the process to address the others.<\/p>\n<h3>Is now a good time to sell to a DSO, given the current market?<\/h3>\n<p>The DSO acquisition market has shifted from its peak. Deal structures in the current environment can feature more contingencies, more earnout weight, and less upfront cash than transactions completed a few years ago, and some platforms that expanded aggressively on leverage are now under financial pressure. At the same time, demand for premier, well-documented practices with strong EBITDA margins, durable hygiene economics, and clean financials remains meaningful, and valuations for that tier of practice continue to be competitive. The right time to sell depends on your specific practice\u2019s financials, your personal timeline, and which buyers are actively acquiring in your specialty and geography right now. McLerran &amp; Associates can provide a candid view of how your practice is positioned in the current market, and if the timing does not appear favorable, the firm can update your valuation later rather than encourage a deal that does not serve your interests.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Learn to evaluate DSO buyers before selling your dental practice. McLerran &#038; Associates helps you ask the right questions and avoid costly mistakes.<\/p>\n","protected":false},"author":1,"featured_media":301,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"inline_featured_image":false,"footnotes":""},"categories":[1],"tags":[],"class_list":["post-302","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-uncategorized"],"_links":{"self":[{"href":"https:\/\/dentaltransitions.com\/articles\/wp-json\/wp\/v2\/posts\/302","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/dentaltransitions.com\/articles\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/dentaltransitions.com\/articles\/wp-json\/wp\/v2\/types\/post"}],"replies":[{"embeddable":true,"href":"https:\/\/dentaltransitions.com\/articles\/wp-json\/wp\/v2\/comments?post=302"}],"version-history":[{"count":0,"href":"https:\/\/dentaltransitions.com\/articles\/wp-json\/wp\/v2\/posts\/302\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/dentaltransitions.com\/articles\/wp-json\/wp\/v2\/media\/301"}],"wp:attachment":[{"href":"https:\/\/dentaltransitions.com\/articles\/wp-json\/wp\/v2\/media?parent=302"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/dentaltransitions.com\/articles\/wp-json\/wp\/v2\/categories?post=302"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/dentaltransitions.com\/articles\/wp-json\/wp\/v2\/tags?post=302"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}